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nursing homes. As this study was not representative, it cannot be
used to draw reliable conclusions. Therefore, the aim of the
current study was to quantify the number of drug administration
errors in German nursing homes. The focus was on checking the
administration of regularly scheduled solid oral medication.
METHODS: The prospective study was carried out in three
nursing homes during a period of eight weeks. The drug admin-
istration errors were divided into seven categories: wrong time
of administration, wrong dosage, wrong drug, missing drug,
surplus drug, incorrect pill division and damaged drug.
RESULTS: The study included 196 residents. In total, 8798 daily
doses were screened. This equals a total number of 48,512
inspected single medications. On average, every nursing home
resident received 5.4 solid oral drugs per day. In 53% of the
nursing home residents one or more drug administration errors
were detected. Based on the 8798 screened daily doses the error
rate was 7.3%. The majority of all drug supply errors (50%)
occurred in the category incorrect pill division. This is followed
by the category missing drug with 22%, surplus drug with 10%,
wrong time of administration with 8%, damaged drug with 6%,
wrong dosage with 4% and wrong drug with 0%. CONCLU-
SION: The ﬁndings of the study show that there is still a need for
action with regard to drug administration in German nursing
homes.
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OBJECTIVE: The opponents of the socialization of health care
hypothesize that socialization of health care could lead to
decrease quality of care. The aim of our study was to compare
the quality of care delivered to a privately insured population
compared to those covered by government subsidized Medicaid
plan in the same region. METHODS: Administrative claims
data from July 2004 through June 2005 were used from a
private health plan and the Medicaid plan within the same state
in the Southeastern US. Two quality indicators from the Health
Plan Employer Data and Information Set (HEDIS) were adapted
and used to compare compliance rates between the privately
insured and Medicaid populations (Table 1). Based on the speci-
ﬁcations of each indicator, children who met relevant criteria
were identiﬁed as the denominator. Of those, children that
received the indicated intervention were identiﬁed as the
numerator. Population-level rates were calculated for each
quality indicator for both plans. RESULTS: Children in the
private health plan received the indicated quality care much
more frequently than the Medicaid population, with nearly
3-fold differences in compliance rates. Varicella zoster virus
(VZV) vaccines and measles, mumps and rubella (MMR) vac-
cines were included in the analysis for 2 year old children. The
private plan had a denominator of 4222 children and the Med-
icaid plan had 15,653 children for both measures. Eighty-two
percent of private plan children received a VZV vaccine com-
pared to 29% of Medicaid children. Eighty-four percent of
private plan children received an MMR vaccine compared to
29% of Medicaid children. CONCLUSION: Children covered
by Medicaid plans are signiﬁcantly less likely to receive quality
health care than compared to those who have private insurance
coverage. Further studies are needed to investigate to what
degree this wide disparity is driven by socioeconomic factors
and the socialization of health care.
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OBJECTIVE: While bisphosphonates have been available for
many years, new drugs in this class have recently become avail-
able. We sought to understand whether differences exist on
fracture risk and adverse events among oral (i.e., alendronate,
risedronate, ibandronate) and intravenous (i.e., ibandronate,
pamidronate, and zoledronic acid) bisphosphonates available in
the United States in postmenopausal women. METHODS: A
search of the English-language literature in Medline and
Cochrane databases was conducted from 1997 to 2007 using
combinations of these search terms: bisphosphonates, alendr-
onate, risedronate, zoledronic acid, pamidronate, ibandronate,
fracture, adverse events, and osteoporosis. Articles were included
if they were meta-analyses or randomized controlled trials (RCT)
and provided information on fracture risk and adverse events.
RESULTS: In the most recent meta-analysis, alendronate
(n = 12,099 patients; 11 trials) and risedronate (n = 13,795
patients; 6 trials) reduced the risk of vertebral fractures
(RR:0.55, 95%CI 0.45–0.67; RR:0.61, 95%CI 0.50–0.76) and
non-vertebral fractures (RR:0.84, 95%CI 0.74–0.94; RR:0.80,
95%CI 0.72–0.90), including hip fractures (RR:0.61, 95%CI
0.40–0.92; RR:0.74, 95%CI 0.59–0.94). Similarly, in a RCT
among 7765 women, the incidence of vertebral fractures, non-
vertebral, and hip fractures was signiﬁcantly reduced with
zoledronic acid (RR:0.30, 95%CI 0.24–0.38; RR:0.75, 95%CI
0.64–0.87; RR:0.59, 95%CI 0.42–0.83). In contrast, oral iban-
dronate (n = 1952) lowered the risk of vertebral fractures
(RR:0.62, 95%CI 0.41–0.75) but not nonvertebral fractures.
Data on fracture risk with pamidronate were not identiﬁed.
Adverse events were similar between bisphosphonates and
placebo in all included studies, except with zoledronic acid where
serious atrial ﬁbrillation (1.3% vs. 0.5%; p < 0.001), an increase
in Scr >0.5 mg/dL (1.2% vs. 0.4%; p = 0.001), and urinary
protein >2+ (0.5% vs. 0.2%; p = 0.06) were higher with treat-
ment compared to placebo. CONCLUSION: This evidenced-
based literature review shows that clinical differences among
bisphosphonates exist. This suggests that selection of bisphos-
phonates needs to be individualized to maximize the desired
effect and minimize risks.
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OBJECTIVE: Three biological agents (adalimumab, etanercept
and inﬂiximab) are registered for psoriatic arthritis (PsA) by the
EMEA or the FDA. Our objectives were to compare the efﬁcacy
of the available biologicals in PsA and to compare their effect
sizes by standardized improvement criteria of signs and symp-
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